RxDoctor Payments Data

Angela Taylor, MD

Interventional Cardiology · Charlottesville, VANPI 1316969777

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $72,000 of the $119,339 with a category attached, or 60.3%. Boston Scientific accounts for 99.0% of it on its own, with 5 other manufacturers making up the rest. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,339in general payments, 2019–2025

Across 136 payments — averaging $877.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$118K
  • Abiomed$357
  • Shockwave Medical, Inc$286
  • Medtronic$269
  • Verge Medical, Inc.$215
  • Novo Nordisk$116
$147,440in research payments, 2019–2025

Across 23 payments — averaging $6410.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$101K
  • Boston Scientific$46K

What the payments were for

  • Consulting fees$30,30025%
  • Speaking & faculty fees$72,00060%
  • Grants$1350%
  • Travel & lodging$10,3099%
  • Food & beverage$6,5956%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific126$118,097
Abiomed3$357
Shockwave Medical, Inc1$286
Medtronic(2 entities)4$269
Verge Medical, Inc.1$215
Novo Nordisk1$116

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,339 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$64,831
Medicare patients
261
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium21$348
Metoprolol Succinate19$228
Carvedilol13$84
Amlodipine Besylate20$74
Hydrochlorothiazide14$19

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →